Introduction
The influenza virus represents a highly contagious infectious agent whose unpredictable variability does not allow a reliable prophylaxis by the current seasonal vaccines. There is a need for the anti-influenza vaccine inducing a long-term cross-protection not only against seasonal drift variants, but also against occasionally emerging reassortant viruses with the pandemic potential. In recent years the pandemic danger appeared twice. Highly pathogenic H5N1 avian virus causing sporadic infections of humans since 1997 still represents a risk, since it may acquire an ability of transmission from human to human (Webster, 2006) . Further threat is a new swine H1N1 (2009) virus with unpredictable evolution (Garten et al., 2009) . Possibility of its mutation into the more virulent and dangerous form still persists (Hensley and Yewdell, 2009 ). The risk of emerging infections by influenza A viruses of such an HA subtype that did not occur in humans before, forces development of a new strategy for the vaccine development. A new approach consists of the selection of conserved influenza virus antigens that are able to induce heterosubtypic immunity, i.e. the immunity against influenza A viruses of various HA subtypes.
Most of the studies concern eM2 that is a part of proton channel protein playing an important role in the replication of influenza virus (Hay, 2000) . The protective effect induced by eM2 have been described by several authors (Liu et al., 2004; Fan et al., 2004; Katz et al., 2006; Tompkins et al., 2007; De Filette et al., 2008ab; Fiers et al., 2009) .
In this work, we focused on the conserved region of influenza virus HA, the fusion peptide that was selected as a promising inducer of protective immunity. Fusion peptide of HA2 gp is essential for the influenza infection (Cross et al., 2009) . In its native conformation, the peptide is embedded in the interspace between monomers of HA trimer. Under low pH, it is exposed and inserted into the target membrane, thus mediating the fusion of viral and endosomal membranes after virus endocytosis (Skehel and Wiley, 2000) . Antibodies specific to HA stem comprising HA1 and HA2 glycopolypeptides inhibit the fusion of viral and endosomal membranes by preventing the conformation change of HA induced by low pH (Okuno et al., 1993; Imai et al., 1998; Vanlandschoot et al., 1998; Throsby et al., 2008; Sui et al., 2009) . Antibodies specific to the fusion peptide of HA2 gp were shown to reduce in vitro replication of influenza A viruses of various HA subtypes (Varečková et al., 2003b; Lim et al., 2008; Stropkovská et al., 2009; Hashem et al., 2010) . These antibodies most probably inhibit the fusion of membranes by blocking an insertion of fusion peptide into the endosomal membrane (Varečková et al., 2003a,b) . Studies examining in vivo protection efficacy of monoclonal antibodies specific to the fusion peptide were published (Gocník et al., 2007; Prabhu et al., 2009 ), but no effective antiviral protection induced by active immunization with this peptide has been described till now.
In this work, the ability of HA2 fusion peptide to induce cross-protective immune response was compared with that of eM2.
Materials and Methods
Viruses. A/Mississippi/1/85 (H3N2) -"MISS" and A/PR/8/34 (H1N1) -"PR8" were propagated in allantoic fluid of 10-day chicken embryos. Stocks of viruses were stored at -70°C. Viruses were obtained from the collection of viruses of Institute of Virology, Bratislava, Slovak Republic.
Mice. Six week-old female BALB/c mice (Faculty of Medicine, Masaryk University, Brno, Czech Republic) were used in animal experiments. In all experiments presented in this paper, animals were treated according to the European Union standards and the fundamental ethical principles including animal welfare requirements were respected.
Peptides and peptide conjugate.Synthetic peptides eM2 (H3 subtype) (93.94% purity) containing 23 aa (SLLTE VETPIRNEWGSRSNDSSD) with relative molecular mass Mr = 2,592.74 and the fusion peptide HA2 (H3 subtype) (94.8% purity) containing N-terminal 38 aa (GIFGAIAGFIENGWEGM VDGWYGFRHQNSEGTGQAADL) with relative molecular mass Mr = 4,059.44 were synthesized and supplied by ProImmune (USA). Consensus aa sequences of H3 subtype isolated in 1985 represented by A/Memphis/2/1985 (H3N2) (Acc. Nos. ABD61779 and ABD61777 for M2 and HA proteins, respectively) were used as a pattern for constructing synthetic peptides. Sequence of eM2 protein of H3 subtype was modified by substitution of C17, C19 to S17, S19, respectively, to avoid formation of disulphide bonds in the peptide.
Conjugation of synthetic peptides with KLH. Synthetic eM2 or fusion peptides were conjugated with KLH (Sigma) using glutaraldehyde. Briefly, synthetic eM2 or fusion peptide in PBS (2 mg/ml) were mixed with 2 mg/ml of KLH in PBS. Glutaraldehyde was added to the reaction mixture to a final concentration 2.5% and the mixture was incubated for 50 mins at room temperature. The reaction was stopped by addition of glycine (0.03 mol/l) and the mixture was dialyzed against PBS at 4 ºC overnight. Aliquots of the conjugated peptides were stored at -20ºC.
Immunization. Conjugated eM2 or fusion peptide of HA2 gp (30 μg/mouse/dose) emulsified in Freund΄s adjuvant (1:2, v/v) were intraperitoneally administered to mice. Three doses of the antigen were given in 14 day-intervals: first dose with the complete and the second and third dose with incomplete Freund΄s adjuvant. Blood samples were taken before the immunization and 14 days after each injection.
Infection of mice. Two weeks after the last injection, the mice were intranasally inoculated with the lethal dose of homologous MISS (H3N2) or heterologous PR8 (H1N1) virus in a volume of 40 μl. Survival and body weight of mice were recorded daily for 14 days post infection (p.i.). One experimental group comprised 8 animals unless stated otherwise. Results were evaluated statistically using Fisher's exact test. Differences were considered to be significant for P ≤0.05.
ELISA. Fusion peptide (500 ng/100 μl) or eM2 (100 ng/100 μl) were used as antigens and adsorbed overnight at 4°C on 96-well plates. ELISA binding test was performed according to Varečková et al. (2003a) . Titer of antibodies in serum was calculated as the reciprocal serum dilution at the point, where the regression line drawn through the three points of the titration curve crosses the cut-off value. Cut-off was estimated as the average value of 5 negative control samples plus 3-times standard deviation.
Results
To study the immune cross-protection against influenza infection with virus of H3 (MISS) and H1 (PR8) subtypes induced by either eM2 (H3) (aa 2-24) or fusion peptide (aa 1-38 of HA2), we selected peptide sequences derived from influenza virus of H3 subtype found in the NCBI Influenza Virus Sequence Database (Fig. 1) . Since A/Mississippi/1/85 (H3N2) sequence of neither eM2 nor HA2 has been available at the GenBank Database, consensus aa sequences of H3 subtyte isolated in 1985, represented by A/Memphis/2/1985 (H3N2) (Acc. Nos. ABD61779 and ABD61777 for M2 and HA proteins, respectively) were used as pattern for constructing synthetic peptides. eM2 amino acid sequences of viruses of H1 and H3 subtypes selected from the database were conserved except one aa in position 21. The fusion peptide aa 1-38 displayed higher variability than eM2. While the region between aa 3-11 is fully conserved within all HA subtypes, there were several changes differing H3 and H1 subtypes in positions from aa 12-38 (Fig. 1) .
Antibody response to the fusion peptide (aa 1-38 of HA2 gp)
A protective potential of antibodies induced with the conjugated fusion peptide was studied in mice immunized with the synthetic fusion peptide corresponding to the N-terminal part of HA2 gp of hemagglutinin of H3 subtype. A low level of antibodies was detectable after the first dose, which significantly increased after the second dose. The highest titer of antibodies specific to the fusion protein was obtained after the third immunization dose and reached the value of 26,500 (Table 1) . Then, immunized mice were challenged with the influenza viruses of H1 or H3 subtypes and clinical symptoms of the disease were monitored.
Cross-protection of mice immunized with the fusion peptide
Mice immunized with the HA2 fusion peptide conjugated with KLH (n = 6) and control PBS-treated mice (n = 6) were infected with 1 LD 50 ( i.e. 5 x 10 3 PFU) of mouse-adapted strain MISS of homologous subtype. Immunization with the conjugated fusion peptide improved survival rate of mice to 100%, while 50% of the control mice died (P = 0.0909) (Fig. 2a) .
In the further experiment, infectious dose of MISS virus was increased to 2 LD 50 to find out the corresponding level of antiviral protection in immunized mice. Survival rate of immunized mice (n = 15) under these conditions was 46%, while all mice in control group treated with PBS died (P ≤0.05) (Fig. 2c) . Therefore, in cross-protective experiments the infectious dose 1 LD 50 (i.e. 65 PFU) of heterologous challenge virus was used.
The survival of immunized mice infected with the heterologous virus PR8 (H1N1) improved to 87.5% from 37.5% in control group (P = 0.0594) (Fig. 2b) . The course of infection was milder in immunized than in control animals as evaluated in relation to the body weight change and other clinical symptoms like low activity and appearance of scrubby fur (Fig. 2d) . It can be therefore concluded that the immunization of mice with the fusion peptide of HA2 gp conferred a significant protection against the lethal infection with homologous as well as heterologous influenza virus.
Antibody response to the eM2 peptide (aa 2-24) BALB/c
mice were immunized with three doses of eM2 peptide conjugated to KLH. Levels of eM2-specific antibodies linearly increased after the first and second immunization dose. The third injection of peptide increased the antibody level to the titer of 28,800 (Table 1) .
Cross-protection of mice immunized with eM2
To study the protection induced with conjugate KLHeM2, the mice were immunized with three doses of conjugate and infected with homologous MISS (H3N2) or heterologous PR8 (H1N1) virus. All immunized mice survived the infection with both challenge viruses even with the dose 3 LD 50 (P ≤0.05) (Fig. 3a, b) . The immunized mice exhibited milder clinical symptoms and slighter body weight loss than the control mice (Fig. 3c, d ). After the infection with PR8, no survival of mice in control group (P ≤0.05) was observed, whilst in the control group infected with the same infectious dose of MISS virus one mouse survived (P ≤0.05) (Fig. 3b) . The survival as well as severity of clinical symptoms corresponded to the virulence of these two viruses described in our previous experiments evaluating MISS virus as medium virulent and PR8 virus as highly virulent .
Discussion
There is a trend to broaden the protection efficacy of current anti-influenza vaccines in order to avoid the need of yearly vaccination against the seasonal influenza strains. One approach to get closer to the cross-protective vaccine is to utilize conserved antigens capable of inducing heterosubtypic immunity. In this study, we focused on the N-terminal aa 1-38 of HA2 gp of influenza HA comprising the fusion peptide as a potential vaccine candidate (Cross et al., 2009) . The fusion peptide represents the conserved part of HA comprising aa 3-11 that are fully conserved among all HA subtypes of influenza A virus (Nobusawa et al., 1991; Gerhard et al., 2006) . Until now, no effective protection utilizing fusion peptide of HA2 gp as an immunogen capable of eliciting polyclonal antibody response has been described. Horvath et al. (1998) immunized mice with the fusion peptide comprising N-terminal aa 1-13 of HA2 gp, but no effective antibody response has been achieved and no protection studies have been done. We previously proved that monoclonal antibody CF2 recognizing N-terminal aa 1-38 of HA2 gp is able to inhibit the hemolysis mediated by the influenza virus, fusion of cells expressing HA on their surfaces as well as virus-liposome fusion monitored by the resonance energy transfer method (Varečková et al., 2003a) . This antibody reduces the replication of influenza viruses of different HA subtypes as determined by a plaque assay on MDCK cells (Varečková et al., 2003b; Stropkovská et al., 2009) . Monoclonal antibody CF2 confers the protection against lethal infection of mice within a given HA subtype (Gocník et al., 2007) . Based on these results, we supposed that the fusion peptide of HA2 gp itself could induce a protective antibody response against different subtypes of HA. In contrast to Horvath et al. (1998) , we conjugated the fusion peptide aa 1-38 to KLH and immunized mice with three doses, what resulted in a significant antibody response in mice. Protective experiments revealed that the fusion peptide was able to induce cross-protective immune response, most probably mediated by specific antibodies.
The cross-protective potential of eM2 protein was used in this study for a comparison to the ability of the HA2 fusion peptide to induce antibody response and antiviral protection (Katz et al., 2006; Fiers et al., 2009) .
The comparison of two peptides as immunogens showed that eM2 peptide is much more effective inducer of protec- tive immunity than the fusion peptide. This conclusion was supported by the observation that animals immunized with eM2 were protected against the higher dose of infectious virus (at least 3 LD 50 ) in comparison to the mice immunized with the fusion peptide, which were protected against infection up to 2 LD 50 . We believe that the protection induced by fusion peptide up to 2 LD 50 is sufficient for the vaccination purposes. Therefore, we suppose that the fusion peptide as well as eM2 could be useful for the induction of heterosubtypic protective immunity.
This report represents the first description of effective in vivo cross-protection induced by active immunization with the fusion peptide. Based on the fact that fusion peptide of HA2 gp is conserved across influenza viruses and that antibodies against this peptide may moderate the virus infection, a future vaccine design should take into account the enrichment of vaccine with the fusion peptide in properly immunogenic form. It would be of interest to see whether simultaneous application of eM2 and fusion peptides will enhance the cross-protection against influenza infection with viruses of various HA subtypes.
